A summary of the major mechanistic classes of therapeutic antibodies used in nonmalignant hematologic disorders, including complement inhibitors, coagulation-modifying antibodies, and FcRn inhibitors, is presented in Table 3. Here, FCGRT is linked to hematologic disorder.